MLYS Earnings

MLYS reported its FY2025Q4 earnings on 2026-03-09, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.57 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following MLYS's FY2025Q4 earnings announcement on 2026-03-09, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, MLYS's stock price tends to shift by an average of -3.91% in the 10 days leading up to earnings and -5.77% in the 10 days following, providing insight into potential market.

For , analysts estimate MLYS's annual revenue to reach undefined, while the EPS is projected at -0.53. These estimates reflect recent revisions, with revenue estimates revised downward by -27.27% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MLYS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for were revised downward by -27.27%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MLYS's stock price typically moves by -3.91% in the 10 days before its earnings and -5.77% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.53 and revenue of undefined.

The earnings call shows mixed signals: a decrease in net loss and strong intent from healthcare professionals to prescribe lorundrostat are positive, but increased expenses and management's avoidance of specifics during the Q&A raise concerns. The company's confidence in their product and ongoing trials suggests stability, while lack of detailed guidance and partnership updates tempers optimism. These factors balance each other out, leading to a neutral sentiment rating.